Journals / Dicle Tıp Dergisi / 2013 / Cilt: 40 - Sayı: 2

Atriyal fibrilasyon hastalarına epidemiyolojik yaklaşım

Epidemiological approach to the atrial fibrillation patients

Pages
332–339
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, by analyzing the epidemiologi cal studies conducted among AF patients in our country, we aimed to bring literature in data related to our society.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atrial Fibrillation (AF) is the most common arrhythmia observed in clinical practice.
📊
Key Findings & Data:While the thromboembolic events are the most feared complications, these com plications alone are responsible for 15% of all strokes.
💡
Conclusion & Impact:In this study, by analyzing the epidemiologi cal studies conducted among AF patients in our country, we aimed to bring literature in data related to our society.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atrial Fibrillation (AF) is the most common arrhythmia observed in clinical practice. While the thromboembolic events are the most feared complications, these com plications alone are responsible for 15% of all strokes. Anticoagulation therapy is the most effective way to pre vent this significant complication caused by AF. Due to the disadvantages related to the recently launched new oral anticoagulants, warfarin still maintains its dominance as the gold standard agent. Pharmaceutical agents as well as demographic characteristics (age, sex, the type of AF, co-morbidities etc.) of the patients are crucial to provide effective coagulation. Since most of the studies on demographic characteristics of AF patients and the profile of oral anticoagulant use originate from the West and Far East, they do not reflect the real characteristics of our country. In this study, by analyzing the epidemiologi cal studies conducted among AF patients in our country, we aimed to bring literature in data related to our society.

Özet

Atrial fibrilasyon (AF) klinik pratikte en sık görülen arit midir. En korkulan komplikasyonu tromboembolik olaylar olup tüm inmelerin % 15’inden tek başına sorumludur. AF’nin yol açtığı bu önemli komplikasyonu önlemenin en etkin yolu antikoagulasyondur. Antikoagülasyonu sağla mak için son dönemlerde ortaya çıkan yeni oral antiko agülanlarla ilgili çekincelerden dolayı altın standart ajan olarak warfarin hala üstünlüğünü sürdürmektedir. Efektif antikoagülasyon sağlamada kullanılan farmakolojik ajan- ların yanı sıra hastanın demografik özellikleri de (yaş, cinsiyet, AF tipi, komorbid durumlar vb.) büyük önem ta- şımaktadır. AF hastalarının demografik karakteristiği ve oral antikoagülan ilaç kullanım profili ile ilgili yapılan çalış- malar çoğunlukla Batı ve Uzakdoğu kökenli olduğundan ülkemizin gerçek karakteristiğini yansıtmamaktadır. Bu çalışmayla ülkemizde AF hastalarında yapılmış olan epi- demiyolojik çalışmalar analiz edilerek toplumumuz ile ilgili verileri literatüre kazandırmayı amaçladık.

🔖

Cite This Article

ERTAŞ, F. (2013). Atriyal fibrilasyon hastalarına epidemiyolojik yaklaşım. Dicle Tıp Dergisi, Cilt: 40 - Sayı: 2, 332–339. https://ajindex.com/articles/348912

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diag nosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An Tico agulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
  2. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibril lation: the Task Force for the Management of Atrial Fibril lation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429
  3. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691
  4. Rockson SG, Albers GW. Comparing the guidelines: antico agulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardio.l 2004;43: 929- 935
  5. Atarashi H, Inoue H, Okumura K, et al. J-RHYTHM Reg- istry Investigators. Present status of anticoagulation treat ment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 2011;75:1328-1333
  6. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibril lation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729- 1736
  7. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423-434
  8. Shin HW, Kim YN, Bae HJ, et al. KORAF Investigator. Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibril lation Investigation. Korean Circ J 2012;42:113-117
  9. Goto S, Bhatt DL, Röther J, et al. REACH Registry Investi gators.Prevalence, clinical profile, and cardiovascular out comes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863 10. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844
  10. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-2461
  11. Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardio